Perindopril - angiotensin-converting enzyme inhibitor is approved for usage

Angiotensin-converting Enzyme Inhibitor

The hemodynamic effects of an oral angiotensin-converting enzyme inhibitor, captopril, were evaluated in 10 symptomatic patients with chronic congestive heart failure. In all patients there was a significant increase in cardiac output (average 28%), stroke volume (49%), and stroke work index (26%), along with a decrease in pulmonary capillary wedge pressure (48%), indicating improved left ventr...

Angiotensin-converting Enzyme Inhibitor

The effects of angiotensin-converting enzyme inhibitor (CEI) SQ14225 on infarct size and regional myocardial blood flow were studied in 21 anesthetized dogs subjected to 6 hours of coronary occlusion. An area of myocardium at risk of necrosis was determined in vivo after 15 minutes of coronary occlusion but before CEI treatment (AR1) using an autoradiographic technique and after treatment after...

Angiotensin Converting Enzyme in Sarcoidosis

Inhibitor binding assay for angiotensin-converting enzyme.

We describe a new principle for the determination of enzymes, here applied to angiotensin-converting enzyme (ACE, EC 3.4.15.1) in human serum. The enzyme inhibitor binding assay is based on specific binding of labeled inhibitor to the active center of the enzyme. Serum (10-15 microL) is incubated with 125I-labeled ACE inhibitor (" 351A ," a p- hydroxybenzamidine derivative of N-(1-carboxy-3-phe...

P23: The Effects of Captopril, as Angiotensin Converting Enzyme Inhibitor, on LPS-Induced Systemic Inflammation

It has been shown that the renin-angiotensin system (RAS) plays key roles in the inflammation process. Imbalance in the oxidant-antioxidant system is one of the major causes of inflammation. In the present study, the effects of captopril on total and differential WBC, oxidative stress in systemic inflammation produced by lipopolysaccharide (LPS) were investigated. The rats were divided to: cont...